Skip to content

Help Paying for HIV and Hepatitis Treatment

  • Chad Cipiti

Health insurance co-payment (co-pay) programs and patient drug assistance programs (PAPs) are critical services for thousands of U.S. residents with HIV and/or viral hepatitis who face out-of-pocket expenses associated with their treatment. The Fair Pricing Coalition (FPC) has negotiated co-pay…

Read more

Undetectable Is Not Always Enough

  • Chad Cipiti

Immunologic nonresponders face increased risk of illness, but lack therapeutic options By Richard Jefferys A subset of people on antiretroviral therapy (ART) experience limited or no recovery of CD4 T-cell counts despite achieving and maintaining undetectable viral loads. Various terms…

Read more

Preparing for Generics

  • Chad Cipiti

The push for affordable HIV treatment doesn’t end with patent expirations By Tim Horn Expiry of guidelines-preferred and -alternative first-line ARTs The United States is on course for some much-needed economic relief from the crippling cost of HIV treatment, with…

Read more

Razing the House of Cards

  • Chad Cipiti

The discovery of HAART and the push for evidence-based HIV treatment By Mark Harrington This is the third in a series looking back at the first two decades of TAG’s work to speed up AIDS research. In Part I: TAG’s…

Read more

Ryan White at a Crossroads

  • Chad Cipiti

Preparing to defend and reshape a still-critical program By Coco Jervis An increasing demand for services, coupled with significant fiscal retrenchment among federal and state agencies, leaves the Ryan White HIV/AIDS CARE Act-funded program at a crossroads. But advocacy strategies…

Read more

Advancing Research, Securing Access

  • Chad Cipiti

By Mark Harrington Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and…

Read more

TAGline Spring 2013

  • Chad Cipiti
Advancing Research, Securing Access: Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and two of its insidious comorbidities, viral hepatitis and tuberculosis. Many of these challenges are inextricably intertwined, as we highlight in this issue focusing on specific clinical research and treatment-access hurdles threatening progress for all three diseases.
Read more

Revitalizing the U.S. National HIV/AIDS Strategy

  • Chad Cipiti

April 2013 On December 11–12, 2012, in Washington, D.C., Treatment Action Group (TAG) hosted a meeting of HIV advocates, service providers, and researchers from across the United States (U.S.) to review the current state of the national HIV response and…

Read more

Beyond ARVs: Advocacy for Non-AIDS Disease Management

  • Chad Cipiti

by Tim Horn Fact: If we’re going to make headway in preventing and treating non-AIDS-related health complications among people with HIV, which are very much on the rise and a serious risk to disease-free survival, we’re going to need the…

Read more
Back To Top